142 related articles for article (PubMed ID: 21289942)
1. Assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical.
Mittendorf T; Nocon M; Roll S; Mühlberger N; Sroczynski G; Siebert U; Willich SN; von der Schulenburg JM
GMS Health Technol Assess; 2007 Sep; 3():Doc08. PubMed ID: 21289942
[TBL] [Abstract][Full Text] [Related]
2. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
[TBL] [Abstract][Full Text] [Related]
3. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
Della Palma P; Moresco L; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
[TBL] [Abstract][Full Text] [Related]
4. Anal dysplasia screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(4):1-43. PubMed ID: 23074504
[TBL] [Abstract][Full Text] [Related]
5. Review on the medical and health economic evidence for an inclusion of colposcopy in primary screening programs for cervical cancer.
Nocon M; Mittendorf T; Roll S; Greiner W; Willich SN; von der Schulenburg JM
GMS Health Technol Assess; 2007 Aug; 3():Doc07. PubMed ID: 21289941
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
Eur J Cancer; 2011 Jul; 47(11):1633-46. PubMed ID: 21482103
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors.
Damm O; Nocon M; Roll S; Vauth C; Willich S; Greiner W
GMS Health Technol Assess; 2009 Mar; 5():Doc04. PubMed ID: 21289891
[TBL] [Abstract][Full Text] [Related]
8. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
9. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
10. Screening for cervical cancer: new alternatives and research.
Lörincz AT
Salud Publica Mex; 2003; 45 Suppl 3():S376-87. PubMed ID: 14746031
[TBL] [Abstract][Full Text] [Related]
11. The health and economic effects of HPV DNA screening in The Netherlands.
Berkhof J; Coupé VM; Bogaards JA; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ
Int J Cancer; 2010 Nov; 127(9):2147-58. PubMed ID: 20112339
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health.
Mühlberger N; Sroczynski G; Esteban E; Mittendorf T; Miksad RA; Siebert U
Int J Technol Assess Health Care; 2008; 24(2):184-92. PubMed ID: 18400122
[TBL] [Abstract][Full Text] [Related]
13. Primary HPV-DNA screening in women under 30 years of age: health technology assessment.
Garzón-Olivares CD; Grillo-Ardila CF; Amaya-Guio J; Vallejo-Ortega MT; Diaz-Cruz LA; Fernández-Motta C; Gomez-Motta ADP; Barrera AT; Trujillo-Sánchez LM; Pérez-Moreno CH; Bonilla-Osma LJ; Fernández-Mercado R; Giraldo-Méndez NA; Caro-Caro JE; Ramírez-Corredor AL; Rodríguez-Hernádez DM
Rev Colomb Obstet Ginecol; 2022 Jun; 73(2):203-222. PubMed ID: 35939411
[TBL] [Abstract][Full Text] [Related]
14. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany.
Petry KU; Barth C; Wasem J; Neumann A
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():132-139. PubMed ID: 28363186
[TBL] [Abstract][Full Text] [Related]
15. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol.
Teixeira JC; Vale DB; Bragança JF; Campos CS; Discacciati MG; Zeferino LC
BMC Public Health; 2020 Apr; 20(1):576. PubMed ID: 32345284
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ
J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]